Physician profile
Allan E Rodriguez
NPI 1720010796
$14,656.37
in general payments reported to CMS, 2019-2025
8 companies · $3,213 in 2025
The $3,213 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,620 · 2020: $336 · 2021: $533 · 2022: $2,359 · 2023: $389 · 2024: $206 · 2025: $3,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,660 · Food and Beverage: $934 · Travel and Lodging: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,660.00 |
| Food and Beverage | $933.59 |
| Travel and Lodging | $215.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13,350.39 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $583.07 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Janssen Products, LP | $388.89 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $133.41 | 2019-2022 | |
| Theratechnologies INC. | $82.18 | 2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $52.28 | 2019-2021 | |
| Napo Pharmaceuticals INC | $41.43 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $24.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.